γ-chain dysfibrinogenemias: Molecular structure-function relationships of naturally occurring mutations in the γ chain of human fibrinogen

Blood

Volumn 92, Issue 7, 1998, Pages 2195-2212

  Côté, Hélène C F ^b   Lord, Susan T ^b   Pratt, Kathleen P ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN;

AMINO ACID SUBSTITUTION; CHEMICAL STRUCTURE; CRYSTAL STRUCTURE; DISEASE ASSOCIATION; DYSFIBRINOGENEMIA; HYPERCOAGULABILITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SCANNING ELECTRON MICROSCOPY; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THROMBOSIS;

EID: 0032189655     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.7.2195     Document Type: Review

References (200)

1. Shafer JA, Higgins DL: Human fibrinogen. Crit Rev Clin Lab Sci 26:1, 1988
2. Henschen AH: Human fibrinogen - structural variants and functional sites. Thromb Haemost 70:42, 1993
3. Doolittle RF: Fibrinogen and fibrin, in Bloom F, Forbes CD, Thomas DP, Tuddenham EGD (eds): Haemostasis and Thrombosis, vol 1. Edinburgh, UK, Churchill Livingstone, 1994, p 491
4. Lord ST: Fibrinogen, in High KA, Roberts HR (eds): Molecular Basis of Thrombosis and Hemostasis. New York, NY, Dekker, 1995, p 51
5. Blombäck B: Fibrinogen and fibrin-proteins with complex roles in hemostasis and thrombosis. Thromb Res 83:1, 1996
6. Mosesson M: Fibrinogen and fibrin polymerization: Appraisal of the binding events that accompany fibrin generation and fibrin clot assembly. Blood Coagul Fibrinol 8:257, 1997
7. Nussenweig V, Seligmann M, Pelmont J, Grabar P: Les produits de dégradation du fibrinogène humain par la plasmine. 1-Séparation et propriétés physico-chimiques. Ann Inst Pasteur 100:377, 1961
8. Veklich YI, Gorkun OV, Medved LV, Nieuwenhuizen W, Weisel JW: Carboxyl-terminal portions of the α chains of fibrinogen and fibrin. Localization by electron microscopy and the effects of isolated αC fragments on polymerization. J Biol Chem 268:13577, 1993
9. Gorkun OV, Veklich YI, Medved LV, Henschen AH, Weisel JW: Role of the αC domains of fibrin in clot formation. Biochemistry 33:6986, 1994
10. Hantgan R, McDonagh J, Hermans J: Fibrin assembly. Ann NY Acad Sci 408:344, 1983
11. Olexa SA, Budzynski AZ: Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci USA 77:1374, 1980
12. Doolittle RF, Laudano AP: Synthetic peptide probes on the location of fibrin polymerization sites. Protides Biological Fluids 28:311, 1980
13. Hasegawa N, Sasaki S: Location of the binding site "b" for lateral polymerization of fibrin. Thromb Res 57:183, 1990
14. Medved LV, Litvinovich SV, Ugarova TP, Lukinova NI, Kalikhevich VN, Ardemasova ZA: Localization of a fibrin polymerization site complementary to Gly-His-Arg sequence. FEBS Lett 320:239, 1993
15. Blombäck B, Blombäck M, Nilsson IM: Coagulation studies on "Reptilase", an extract of the venom from Bothrops jararaca. Thromb Diath Haemor 1:76, 1957
16. Shainoff JR, Page IH: Cofibrins and fibrin-intermediates as indicators of thrombin activity in vivo. Circ Res 8:1013, 1960
17. Shainoff JR, Dardik BN: Fibrinopeptide B in fibrin assembly and metabolism: Physiologic significance in delayed release of the peptide. Ann NY Acad Sci 408:254, 1983
18. Weisel JW, Veklich Y, Gorkun O: The sequence of cleavage of fibrinopeptides from fibrinogen is important for protofibril formation and enhancement of lateral aggregation in fibrin clots. J Mol Biol 232:285, 1993
19. Lorand L, Konishi K, Jacobsen A: Transpeptidation mechanism in blood clotting. Nature 194:1148, 1962
20. Pisano JJ, Finlayson JS, Peyton MP: Cross-link in fibrin polymerized by factor XIII: ε-(γ-glutamyl)lysine. Science 160:892, 1968
21. McKee PA, Schwartz ML, Pizzo SV, Hill RL: Cross-linking of fibrin by fibrin-stabilizing factor. Ann NY Acad Sci 202:127, 1972
22. Chen R, Doolittle RF: γ-γ cross-linking sites in human and bovine fibrin. Biochemistry 10:4487, 1971
23. Cierniewski CS, Budzynski AZ: Localization of the crosslinking site of GPRVVERHK in the γ-chain of human fibrinogen. Eur J Biochem 218:321, 1993
24. McDonagh RP, McDonagh J, Blombäck M, Blombäck B: Crosslinking of human fibrin: Evidence for intermolecular crosslinking involving α-chains. FEBS Lett 14:33, 1971
25. Cottrell B A, Strong DD, Watt KW, Doolittle RF: Amino acid sequence studies on the a chain of human fibrinogen. Exact location of cross-linking acceptor sites. Biochemistry 18:5405, 1979
26. Matsuka YV, Medved LV, Migliorini MM, Ingham KC: Factor XIIIa-catalyzed cross-linking of recombinant αC fragments of human fibrinogen. Biochemistry 35:5810, 1996
27. Sobel JH, Gawinowicz MA: Identification of the a chain lysine donor sites involved in factor XIIIa fibrin cross-linking. J Biol Chem 271:19288, 1996
28. McKee PA, Mattock P, Hill RL: Subunit structure of human fibrinogen, soluble fibrin, and cross-linked insoluble fibrin. Proc Natl Acad Sci USA 66:738, 1970
29. Shen L, Lorand L: Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. J Clin Invest 71:1336, 1983
30. Jansen JW, Haverkate F, Koopman J, Niewenhuisen HK, Kluft C, Boschman TA: Influence of factor XIIIa activity on whole blood clot lysis in vitro. Thromb Haemost 57:171, 1987
31. Francis CW, Marder VJ: Increased resistance to plasmic degradation of fibrin with highly crosslinked α-polymer chains formed at high factor XIII concentrations. Blood 71:1361, 1988
32. Siebenlist KR, Mosesson MW: Progressive cross-linking of fibrin γ chains increases resistance to fibrinolysis. J Biol Chem 269:28414, 1994
33. Wiman B, Collen D: Molecular mechanism of physiological fibrinolysis. Nature 272:549, 1978
34. Hoylaerts M, Rijken DC, Lijnen HR, Collen D: Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 257:2912, 1982
35. Ranby M: Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 704:461, 1982
36. Suenson E, Bjerrum P, Holm A, Lind B, Meldal M, Seimer J, Petersen LC: The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation. J Biol Chem 265:22228, 1990
37. Bauer R, Hansen SL, Jones G, Suenson E, Thorsen S, Ogendal L: Fibrin structures during tissue-type plasminogen activator-mediated fibrinolysis studied by laser light scattering: Relation to fibrin enhancement of plasminogen activation. Eur Biophys J 23:239, 1994
38. Phillips DR, Charo IF, Parise LV, Fitzgerald LA: The platelet membrane glycoprotein IIb-IIIa complex. Blood 71:831, 1988
39. Dejana E, Colella S, Languino LR, Balconi G, Corbascio GC, Marchisio PC: Fibrinogen induces adhesion, spreading, and microfilament organization of human endothelial cells in vitro. J Cell Biol 104:1403, 1987
40. Dejana E, Zanetti A, Conforti G: Biochemical and functional characteristics of fibrinogen interaction with endothelial cells. Haemostasis 18:262, 1988
41. Languino LR, Plescia J, Duperray A, Brian AA, Plow EF, Geltosky JE, Altieri DC: Fibrinogen mediates leukocyte adhesion to vascular endothelium through an ICAM-1-dependent pathway. Cell 73:1423, 1993
42. Sriramarao P, Languino LR, Altieri DC: Fibrinogen mediates leukocyte-endothelium bridging in vivo at low shear forces. Blood 88:3416, 1996
43. 1 on endothelial cells. J Biol Chem 272:5360, 1997
44. Altieri DC, Bader R, Mannucci PM, Edgington TS: Oligospecificity of the cellular adhesion receptor Mac-1 encompasses an inducible recognition specificity for fibrinogen. J Cell Biol 107:1893, 1988
45. Wright SD, Weitz JI, Huang AJ, Levin SM, Silverstein SC, Loike JD: Complement receptor type three (CD11b/CDI 8) of human polymorphonuclear leukocytes recognizes fibrinogen. Proc Natl Acad Sci USA 85:7734, 1988
46. Trezzini C, Jungi TW, Kuhnert P, Peterhans E: Fibrinogen association with human monocytes: Evidence for constitutive expression of fibrinogen receptors and for involvement of Mac-1 (CD18, CR3) in the binding. Biochem Biophys Res Commun 156:477, 1988
47. Gustafson EJ, Lukasiewicz H, Wachtfogel YT, Norton KJ, Schmaier AH, Niewiarowski S, Colman RW: High molecular weight kininogen inhibits fibrinogen binding to cytoadhesins of neutrophils and platelets. J Cell Biol 109:377, 1989
48. Godyna S, Diaz Ricart M, Argraves WS: Fibulin-1 mediates platelet adhesion via a bridge of fibrinogen. Blood 88:2569, 1996
49. Nieuwenhuizen W, Voskuilen M, Vermond A, Haverkate F, Hermans J: A fibrinogen fragment D (D intermediate) with calcium binding but without anticlotting properties. Biochirn Biophys Acta 707:190, 1982
50. Southan C, Thompson E, Panico M, Etienne T, Morris HR, Lane DA: Characterization of peptides cleaved by plasmin from the C-terminal polymerization domain of human fibrinogen. J Biol Chem 260:13095, 1985
51. Dang CV, Ebert RF, Bell WR; Localization of a fibrinogen calcium binding site between γ-subunit positions 311 and 336 by terbium fluorescence. J Biol Chem 260:9713, 1985
52. Váradi A, Scheraga HA: Localization of segments essential for polymerization and for calcium binding in the γ-chain of human fibrinogen. Biochemistry 25:519, 1986
53. Shimizu A, Nagel GM, Doolittle RF: Photoaffinity labeling of the primary fibrin polymerization site: isolation and characterization of a labeled cyanogen bromide fragment corresponding to γ-chain residues 337-379. Proc Natl Acad Sci USA 89:2888, 1992
54. Yamazumi K, Doolittle RF: Photoaffinity labeling of the primary fibrin polymerization site: localization of the label to γ-chain Tyr-363. Proc Natl Acad Sci USA 89:2893, 1992
55. Yee VC, Pratt KP, Côté HCF, Le Trong I, Chung DW, Davie EW, Stenkamp RE, Teller DC: Crystal structure of a 30 kDa C-terminal fragment from the γ chain of human fibrinogen. Structure 5:125, 1997
56. Pratt KP, Côté HCF, Chung DW, Stenkamp RE, Davie EW: The primary fibrin polymerization pocket: Three-dimensional structure of a 30-kDa C-terminal γ chain fragment complexed with the peptide Gly-Pro-Arg-Pro. Proc Natl Acad Sci USA 94:7176, 1997
57. Kloczewiak M, Timmons S, Hawiger J: Recognition site for the platelet receptor is present on the 15-residue carboxy-terminal fragment of the γ chain of human fibrinogen and is not involved in the fibrin polymerization reaction. Thromb Res 29:249, 1983
58. Kloczewiak M, Timmons S, Lukas TJ, Hawiger J: Platelet receptor recognition site on human fibrinogen. Synthesis and structure-function relationship of peptides corresponding to the carboxy-terminal segment of the γ chain. Biochemistry 23:1767, 1984
59. Hettasch JM, Bolyard MG, Lord ST: The residues AGDV of recombinant γ chains of human fibrinogen must be carboxy-terminal to support human platelet aggregation. Thromb Haemost 68:701, 1992
60. Rooney MM, Parise LV, Lord ST: Dissecting clot retraction and platelet aggregation. Clot retraction does not require an intact fibrinogen γ chain C terminus. J Biol Chem 271:8553, 1996
61. Trezzini C, Jungi TW, Maly FE, Vittoz M, Peterhans E: Low-affinity interaction of fibrinogen carboxy-gamma terminus with human monocytes induces an oxidative burst and modulates effector functions. Biochem Biophys Res Commun 165:7, 1989
62. 2, Mac-1) and promotes leukocyte adhesion. J Biol Chem 268:1847, 1993
63. Medved L, Litvinovich S, Ugarova T, Matsuka Y, Ingham K: Domain structure and functional activity of the recombinant human fibrinogen γ-module (γ148-411). Biochemistry 36:4685, 1997
64. Váradi A, Patthy L: Location of plasminogen-binding sites in human fibrin(ogen). Biochemistry 22:2440, 1983
65. Schielen WJ, Adams HP, van Leuven K, Voskuilen M, Tesser GI, Nieuwenhuizen W: The sequence γ-(312-324) is a fibrin-specific epitope. Blood 77:2169, 1991
66. Yonekawa O, Voskuilen M, Nieuwenhuizen W: Localization in the fibrinogen γ-chain of a new site that is involved in the acceleration of the tissue-type plasmmogen activator-catalysed activation of plasminogen. Biochem J 283:187, 1992
67. Kaczmarek E, Lee MH, McDonagh J: Initial interaction between fibrin and tissue plasminogen activator (t-PA). The Gly-Pro-Arg-Pro binding site on fibrin(ogen) is important for t-PA activity. J Biol Chem 268:2474, 1993
68. Nieuwenhuizen W: Sites in fibrin involved in the acceleration of plasminogen activation by t-PA. Possible role of fibrin polymerisation. Thromb Res 75:343, 1994
69. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG: Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study [see comments]. Lancet 2:533, 1986
70. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB: Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258:1183, 1987
71. Kannel WB, D'Agostino RB, Belanger AJ: Update on fibrinogen as a cardiovascular risk factor. Ann Epidemiol 2:457, 1992
72. Ernst E: Fibrinogen: An important risk factor for atherothrombotic diseases. Ann Med 26:15, 1994
73. de la Serna G: Fibrinogen: A major new risk factor for cardiovascular disease. A review of the literature. J Fam Pract 39:468, 1994
74. Ernst E: Fibrinogen: Its emerging role as a cardiovascular risk factor. Angiology 45:87, 1994
75. Fatah K, Hamsten A, Blombäck B, Blombäck M: Fibrin gel network characteristics and coronary heart disease: Relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 68:130, 1992
76. Dintenfass L: Erythrocyte aggregation and cardiovascular risk factors. Clin Hemorheol 8:237, 1988
77. Blombäck B, Carlsson K, Fatah K, Hessel B, Procyk R: Fibrin in human plasma: Gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 75:521, 1994
78. Galanakis DK: Fibrinogen anomalies and disease. A clinical update. Hematol Oncol Clin North Am 6:1171, 1992
79. Miletich JP, Prescott SM, White R, Majerus PW, Bovill EG: Inherited predisposition to thrombosis. Cell 72:477, 1993
80. Eby CS: A review of the hypercoagulable state. Hematol Oncol Clin North Am 7:1121, 1993
81. Nachman RL, Silverstein R: Hypercoagulable states. Ann Intern Med 119:819, 1993 [see comments in Ann Intern Med 119:819, 1993]
82. Nachman RL, Silverstein R: Hypercoagulable states. Ann Intern Med 119:819, 1993 [see comments in Ann Intern Med 119:819, 1993]
83. Sham RL, Francis CW: Evaluation of mild bleeding disorders and easy bruising. Blood Rev 8:98, 1994
84. Schafer AI: Hypercoagulable states: Molecular genetics to clinical practice. Lancet 344:1739, 1994
85. Haverkate F, Samama M: Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 73:151, 1995
86. Rosendaal FR: Risk factors for venous thrombosis: Prevalence, risk, and interaction. Semin Hematol 34:171, 1997
87. Koeleman BPC, Reitsma PH, Bertina RM: Familial thrombophilia: A complex genetic disorder. Semin Hematol 34:256, 1997
88. Koopman J, Haverkate F: Hereditary variants of human fibrinogens, in Bloom F, Forbes CD, Thomas DP, Tuddenham EGD (eds): Haemostasis and Thrombosis, vol 1. Edinburgh, UK, Churchill Livingstone, 1994, p 515
89. Ebert RF (ed): Index of Variant Human Fibrinogens. Boca Raton, FL, CRC, 1994
90. Hall C, Slayter H: The fibrinogen molecule: Its size, shape, and mode of polymerization. J Biophys Biochem Cyt 5:11, 1959
91. Stryer L, Cohen C, Langridge R: Axial period of fibrinogen and fibrin. Nature 197:793, 1963
92. Cohen C, Tooney NM: Crystallisation of a modified ribrinogen. Nature 251:659, 1974
93. Weisel JW, Warren SG, Cohen C: Crystals of modified fibrinogen: Size, shape and packing of molecules. J Mol Biol 126:159, 1978
94. Fowler WE, Erickson HP: Trinodular structure of fibrinogen. Confirmation by both shadowing and negative stain electron microscopy. J Mol Biol 134:241, 1979
95. Weisel JW, Stauffacher CV, Bullitt E, Cohen C: A model for fibrinogen: Domains and sequence. Science 230:1388, 1985
96. Siebenlist KR, Mosesson MW, Di Orio JP, Tavori S, Tatarsky I, Rimon A: The polymerization of fibrin prepared from fibrinogen Haifa (γ275Arg → His). Thromb Haemost 62:875, 1989
97. Koopman J, Haverkate F, Grimbergen J, Lord ST, Mosesson MW, DiOrio JP, Siebenlist KS, Legrand C, Soria J, Soria C, Caen JP: Molecular basis for fibrinogen Dusart (Aα 554 Arg → Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest 91:1637, 1993
98. Spraggon G, Everse SJ, Doolittle RF: Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. Nature 389:455, 1997
99. Ĉté HCF, Pratt KP, Davie EW, Chung DW: The polymerization pocket "a" within the carboxyl-terminal region of the γ chain of human fibrinogen is adjacent to but independent from the calcium-binding site. J Biol Chem 272:23792, 1997
100. Doolittle RF: A detailed consideration of a principal domain of vertebrate fibrinogen and its relatives. Protein Sci 1:1563, 1992
101. Mosesson MW, Siebenlist KR, DiOrio JP, Matsuda M, Hainfeld JF, Wall JS: The role of fibrinogen D domain intermolecular association sites in the polymerization of fibrin and ribrinogen Tokyo II (γ275 Arg → Cys). J Clin Invest 96:1053, 1995
102. Niwa K, Takebe M, Sugo T, Kawata Y, Mimuro J, Asakura S, Sakata Y, Mizushima J, Maeda A, Endo H, Matsuda M: A γ Gly-268 to Glu substitution is responsible for impaired fibrin assembly in a homozygous dysfibrinogen Kurashiki I. Blood 87:4686, 1996
103. Mayo KH, Burke C, Lindon JN, Kloczewiak M: 1H NMR sequential assignments and secondary structure analysis of human fibrinogen γ-chain C-terminal residues 385-411, Biochemistry 29:3277, 1990
104. Blumenstein M, Matsueda GR, Tiffimons S, Hawiger J: A β-turn is present in the 392-411 segment of the human fibrinogen γ-chain. Effects of structural changes in this segment on affinity to antibody 4A5. Biochemistry 31:10692, 1992
105. Donahue JP, Patel H, Anderson WF, Hawiger J: Three-dimensional structure of the platelet integrin recognition segment of the fibrinogen γ chain obtained by carrier protein-driven crystallization. Proc Natl Acad Sci USA 91:12178, 1994
106. Fan F, Mayo KH: Effect of pH on the conformation and backbone dynamics of a 27-residue peptide in trifluorethanol. An NMR and CD study. J Biol Chem 270:24693, 1995
107. Mayo KH, Fan F, Beavers MP, Eckardt A, Keane P, Hoekstra WJ, Andrade-Gordon P: Integrin receptor GPIIb/IIIa bound state conformation of the fibrinogen γ-chain C-terminal peptide 400-411: NMR and transfer NOE studies. Biochemistry 35:4434, 1996
108. Dang CV, Bell WR, Shuman M: The normal and morbid biology of fibrinogen. Am J Med 87:567, 1989
109. Matsuda M, Yoshida N, Terukina S, Yamazumi K, Maekawa H: Molecular abnormalities of fibrinogen - The present status of structure elucidation, in Matsuda M, Iwanaga S, Takada A, Henschen A (eds): Fibrinogen 4. Current Basic and Clinical aspects. Amsterdam, The Netherlands, Elsevier, 1990, p 139
110. Galanakis DK: Inherited dysfibrinogenemia: Emerging abnormal structure associations with pathologic and nonpathologic dysfunctions. Semin Thromb Hemost 19:386, 1993
111. Matsuda M: The structure-function relationship of hereditary dysfibrinogens. Int J Hematol 64:167, 1996
112. Brown WM, Dziegielewska KM, Foreman RC, Saunders NR: Nucleotide and deduced amino acid sequence of a γ subunit of bovine fibrinogen. Nucleic Acids Res 17:6397, 1989
113. Strong DD, Moore M, Cottrell BA, Bohonus VL, Pontes M, Evans B, Riley M, Doolittle RF: Lamprey fibrinogen γ chain: Cloning, cDNA sequencing, and general characterization. Biochemistry 24:92, 1985
114. Terukina S, Matsuda M, Hirata H, Takeda Y, Miyata T, Takao T, Shimonishi Y: Substitution of γ Arg-275 by Cys in an abnormal fibrinogen, "fibrinogen Osaka II." Evidence for a unique solitary cystine structure at the mutation site. J Biol Chem 263:13579, 1988
115. Yoshida N, Ota K, Moroi M, Matsuda M: An apparently higher molecular weight γ-chain variant in a new congenital abnormal fibrinogen Tochigi characterized by the replacement of γ arginine-275 by cysteine. Blood 71:480, 1988
116. Terukina S, Matsuda M, Yoshida N, Yamazumi K, Takeda Y, Takano T: Two abnormal fibrinogens designated as Osaka II and Morioka with a hitherto unidentified amino acid substitution; γArg-275 by Cys (abstr). Thromb Haemost 58:515, 1987
117. Ebert RF, Bell WR: Fibrinogen Baltimore IV: Congenital dysfibrinogenemia with delayed fibrin monomer polymerization. Thromb Res 38:121, 1985
118. Schmelzer CH, Ebert RF, Bell WR: Fibrinogen Baltimore IV: Congenital dysfibrinogenemia with a γ275 (Arg → Cys) substitution. Thromb Res 56:307, 1989
119. Matsuda M, Baba M, Morimoto K, Nakamikawa C: "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules. J Clin Invest 72:1034, 1983
120. Steinmann C, Bögli C, Jungo M, Lämmle B, Heinemann G, Wermuth B, Redaelli R, Baudo F, Furlan M: Fibrinogen Milano V: A congenital dysfibrinogenaemia with a γ275 Arg → Cys substitution. Blood Coagul Fibrinol 5:463, 1994
121. Borrell M, Garí M, Coll I, Vallvé C, Tirado I, Soria JM, Sala N, Muñoz C, Oliver A, García A, Fontcuberta J: Abnormal polymerization and normal binding of plasminogen and t-PA in three new dysfibrinogenaemias: Barcelona III and IV (γArg 275 → His) and Villajoyosa (γArg 275 → Cys). Blood Coagul Fibrinol 6:198, 1995
122. Haverkate F, Timan G, Nieuwenhuizen W: Anticlotting properties of fragments D from human fibrinogen and fibrin. Eur J Clin Invest 9:253, 1979
123. Mosesson MW, Siebenlist KR, Olson JD: Thrombophilia associated with dysfibrinogenemia [fibrinogen Cedar Rapids (γR275C)] and a heterozygous factor V Leiden defect. Thromb Haemost OC-1560:382, 1997 (abstr, suppl)
124. van den Meer FJ, Koster T, Vandenbroucke JP, Briët E, Rosendaal FR: The Leiden thrombophilia study (LETS), Thromb Haemost 78:631, 1997
125. Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, Villalta S, Dazzi F, Girolami A: The risk of recurrent venous thromboembolism in patients with an Arg506 → Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 336:399, 1997
126. Dahlback B: Resistance to activated protein C as risk factor for thrombosis: Molecular mechanisms, laboratory investigation, and clinical management. Semin Hematol 34:217, 1997
127. Reber P, Furlan M, Henschen A, Kaudewitz H, Barbui T, Hilgard P, Nenci GG, Berrettini M, Beck EA: Three abnormal fibrinogen variants with the same amino acid substitution (γ275 Arg → His): Fibrinogens Bergamo II, Essen and Perugia. Thromb Haemost 56:401, 1986
128. Yoshida N, Imaoka S, Hirata H, Matsuda M, Asakura S: Heterozygous abnormal fibrinogen Osaka III with the replacement of γ arginine-275 by histidine has an apparently higher molecular weight γ-chain variant. Thromb Haemost 68:534, 1992
129. Steinmann C, Jungo M, Beck EA, Lämmle B, Furlan M: Fibrinogen Claro - Another dysfunctional fibrinogen variant with γ275 arginine → histidine substitution [published erratum appears in Thromb Res 82:107, 1996]. Thromb Res 81:145, 1996
130. Yamazumi K, Terukina S, Onohara S, Matsuda M: Normal plasmic cleavage of the γ-chain variant of "fibrinogen Saga" with an Arg-275 to His substitution. Thromb Haemost 60:476, 1988
131. Brook JG, Tabori S, Tatarsky I, Hashmonai M, Schramek A: Fibrinogen "Haifa" - A new fibrinogen variant. A case report. Haemostasis 13:277, 1983
132. Soria J, Soria C, Samama M, Tabori S, Kehl M, Henschen A, Nieuwenhuizen W, Rimon A, Tatarski I: Fibrinogen Haifa: Fibrinogen variant with absence of protective effect of calcium on plasmin degradation of gamma chains. Thromb Haemost 57:310, 1987
133. Haverkate F, Timan G: Protective effect of calcium in the plasmin degradation of fibrinogen and fibrin fragments D. Thromb Res 10:803, 1977
134. Beck EA, Charache P, Jackson DP: A new inherited coagulation disorder caused by an abnormal fibrinogen ('Fibrinogen Baltimore'). Nature 208:143, 1965
135. Mosesson MW, Beck EA: Chromatographic, ultracentrifugal, and related studies of fibrinogen "Baltimore." J Clin Invest 48:1656, 1969
136. Beck EA, Shainoff JR, Vogel A, Jackson DP: Functional evaluation of an inherited abnormal fibrinogen: Fibrinogen "Baltimore." J Clin Invest 50:1874, 1971
137. Brown CH, Crowe MF: Defective ex-polymerization in the conversion of fibrinogen Baltimore to fibrin. J Clin Invest 55:1190, 1975
138. Bantia S, Mane SM, Bell WR, Dang CV: Fibrinogen Baltimore I: Polymerization defect associated with a γ292Gly → Val (GGC→GTC) mutation. Blood 76:2279, 1990
139. Wolfenden R, Andersson L, Cullis PM, Southgate CC: Affinities of amino acid side chains for solvent water. Biochemistry 20:849, 1981
140. Wesson L, Eisenberg D: Atomic solvation parameters applied to molecular dynamics of proteins in solution. Protein Sci 1:227, 1992
141. Ebert RF, Bell WR: Fibrinogen Baltimore III: Congenital dysfibrinogenemia with a shortened γ-subunit. Thromb Res 51:251, 1988
142. Bantia S, Bell WR, Dang CV: Polymerization defect of fibrinogen Baltimore III due to a γ Asn308 → Ile mutation. Blood 75:1659, 1990
143. Yoshida N, Okuma M, Moroi M, Matsuda M: A lower molecular weight γ-chain variant in a congenital abnormal fibrinogen (Kyoto). Blood 68:703, 1986
144. Yoshida N, Terukina S, Okuma M, Moroi M, Aoki N, Matsuda M: Characterization of an apparently lower molecular weight γ-chain variant in fibrinogen Kyoto I. The replacement of γ-asparagine 308 by lysine which causes accelerated cleavage of fragment D1 by plasmin and the generation of a new plasmin cleavage site. J Biol Chem 263:13848, 1988
145. Grailhe P, Boyer-Neumann C, Haverkate F, Grimbergen J, Larrieu MJ, Anglés-Cano E: The mutation in fibrinogen Bicêtre II (γ Asn308 → Lys) does not affect the binding of t-PA and plasminogen to fibrin. Blood Coagul Fibrinol 4:679, 1993
146. 308 Asn → Lys (AAT → AAG) mutation associated with bleeding tendency. Br J Haematol 94:526, 1996
147. Yamazumi K, Shimura K, Terukina S, Takahashi N, Matsuda M: A γ methionine-310 to threonine substitution and consequent N-glycosylation at γ asparagine-308 identified in a congenital dysfibrinogenemia associated with posttraumatic bleeding, fibrinogen Asahi. J Clin Invest 83:1590, 1989
148. Yamazumi K, Shimura K, Maekawa H, Muramatsu S, Terukina S, Matsuda M: Delayed intermolecular γ-chain cross-linking by factor XHIa in fibrinogen Asahi characterized by a γ-Met-310 to Thr substitution with an N-glycosylated γ-Asn-308. Blood Coagul Fibrinol 1:557, 1990
149. Dang CV, Shin CK, Bell WR, Nagaswami C, Weisel JW: Fibrinogen sialic acid residues are low affinity calcium-binding sites that influence fibrin assembly. J Biol Chem 264:15104, 1989
150. Martinez J, Palascak J, Peters C: Functional and metabolic properties of human asialofibrinogen. J Lab Clin Med 89:367, 1977
151. Langer BG, Weisel JW, Dinauer PA, Nagaswami C, Bell WR: Deglycosylation of fibrinogen accelerates polymerization and increases lateral aggregation of fibrin fibers. J Biol Chem 263:15056, 1988
152. Maekawa H, Yamazumi K, Muramatsu S, Kaneko M, Hirata H, Takahashi N, Arocha-Pinango CL, Rodriguez S, Nagy H, Perez-Requejo JL, Matsuda M: Fibrinogen Lima: A homozygous dysfibrinogen with an Aα-arginine-141 to serine substitution associated with extra N-glycosylation at Aα-asparagine-139. Impaired fibrin gel formation but normal fibrin-facilitated plasminogen activation catalyzed by tissue-type plasminogen activator. J Clin Invest 90:67, 1992
153. Koopman J, Haverkate F, Briët E, Lord ST: A congenially abnormal fibrinogen (Vlissingen) with a 6-base deletion in the γ-chain gene, causing defective calcium binding and impaired fibrin polymerization. J Biol Chem 266:13456, 1991
154. Takamatsu J, Iwanaga S: Studies on abnormal fibrinogen. Nippon Ketsueki Gakkai Zasshi Acta Haematologica Japan 43:1203, 1980
155. Mizuochi T, Taniguchi T, Asami Y, Takamatsu J, Okude M, Iwanaga S, Kobata A: Comparative studies on the structures of the carbohydrate moieties of human fibrinogen and abnormal fibrinogen Nagoya. J Biochem Tokyo 92:283, 1982
156. Miyata T, Furukawa K, Iwanaga S, Takamatsu J, Saito H: Fibrinogen Nagoya, a replacement of glutamine-329 by arginine in the γ-chain that impairs the polymerization of fibrin monomer. J Biochem Tokyo 105:10, 1989
157. Reber P, Furlan M, Rupp C, Kehl M, Henschen A, Mannucci PM, Beck EA: Characterization of fibrinogen Milano I: Amino acid exchange γ330 Asp → Val impairs fibrin polymerization. Blood 67:1751, 1986
158. Terukina S, Yamazumi K, Okamoto K, Yamashita H, Ito Y, Matsuda M: Fibrinogen Kyoto III: A congenital dysfibrinogen with a γ aspartic acid-330 to tyrosine substitution manifesting impaired fibrin monomer polymerization. Blood 74:2681, 1989
159. Rupp C, Kuyas C, Haeberli A, Furlan M, von Fliedner V, Beck EA: Fibrinogen Bern I and fibrinogen Bern II: 2 hereditary fibrinogen variants with diverse biochemical properties. Schweiz Med Wochenschr 111:1543, 1981
160. Steinmann C, Reber P, Jungo M, Lammle B, Heinemann G, Wermuth B, Furlan M: Fibrinogen Bern I: Substitution γ 337 Asn → Lys is responsible for defective fibrin monomer polymerization. Blood 82:2104, 1993
161. Ménaché D: Constitutional and familial abnormal fibrinogen. Thromb Diath Haemorrh 13:173, 1964 (suppl)
162. Budzynski AZ, Marder VJ, Ménaché D, Guillin M-C: Defect in the gamma polypeptide chain of a congenital abnormal fibrinogen. Nature 252:66, 1974
163. Mosesson MW, Amrani DL, Ménaché D: Studies on the structural abnormality of fibrinogen Paris I. J Clin Invest 57:782, 1976
164. Mosesson MW, Feldmann G, Ménaché D: Electron microscopy of fibrin Paris I. Blood 56:80, 1980
165. Denninger M-H, Jandrot-Perrus M, Elion J, Bertrand O, Homandberg GA, Mosesson MW, Guillin M-C: ADP-induced platelet aggregation depends on the conformation or availability of the terminal gamma chain sequence of fibrinogen. Study of the reactivity of fibrinogen Paris 1. Blood 70:558, 1987
166. Rosenberg JB, Newman PJ, Mosesson MW, Guillin M-C, Amrani DL: Paris I dysfibrinogenemia: A point mutation in intron 8 results in insertion of a 15 amino acid sequence in the fibrinogen γ-chain. Thromb Haemost 69:217, 1993
167. Steinmann C, Bögli C, Jungo M, Lämmle B, Heinemann G, Wermuth B, Redaelli R, Baudo F, Furlan M: A new substitution, 7358 Ser → Cys, in fibrinogen Milano VII causes defective fibrin polymerization. Blood 84:1874, 1994
168. Okumura N, Furihata K, Terasawa F, Nakagoshi R, Ueno I, Katsuyama T: Fibrinogen Matsumoto I: A γ364 Asp → His (GAT → CAT) substitution associated with defective fibrin polymerization. Thromb Haemost 75:887, 1996
169. Bentolila S, Samama MM, Conard J, Horellou MH, Ffrench P: Association of dysfibrinogenemia and thrombosis. Apropos of a family (Fibrinogen Melun) and review of the literature. Ann Med Interne Paris 146:575, 1995
170. Okumura N, Gorkun OV, Lord ST: Severely impaired polymerization of recombinant fibrinogen γ364 Asp → His, the substitution discovered in a heterozygous individual. J Biol Chem 272:29596, 1997
171. Yamazumi K, Doolittle RF: The synthetic peptide Gly-Pro-Arg-Pro-amide limits the plasmic digestion of fibrinogen in the same fashion as calcium ion. Protein Sci 1:1719, 1992
172. Dang CV, Bell WR, Ebert RF, Starksen NF: Protective effect of divalent cations in the plasmin degradation of fibrinogen. Arch Biochem Biophys 238:452, 1985
173. Yoshida N, Hirata H, Morigami Y, Imaoka S, Matsuda M, Yamazumi K, Asakura S: Characterization of an abnormal fibrinogen Osaka V with the replacement of γ-arginine 375 by glycine. The lack of high affinity calcium binding to D-domains and the lack of protective effect of calcium on fibrinolysis. J Biol Chem 267:2753, 1992
174. Purves LR, Lindsey GG, Brown G, Franks J: Stabilization of the plasmin digestion products of fibrinogen and fibrin by calcium ions. Thromb Res 12:473, 1978
175. Nieuwenhuizen W, Vermond A, Nooijen WJ, Haverkate F: Calcium-binding properties of human fibrin(ogen) and degradation products. FEBS Lett 98:257, 1979
176. Marguerie G, Ardaillou N: Potential role of the Aα chain in the binding of calcium to human fibrinogen. Biochim Biophys Acta 701:410, 1982
177. Nieuwenhuizen W, Haverkate F: Calcium-binding regions in fibrinogen. Ann NY Acad Sci 408:92, 1983
178. Ridgway HJ, Brennan SO, Loreth RM, George PM: Fibrinogen Kai sers lautern (γ380 Lys to Asn): A new glycosylated fibrinogen variant with delayed polymerization. Br J Haematol 99:562, 1997
179. Lindsey GG, Brown G, Purves LR: Calcium binding to human fibrinogen - Localization of two calcium specific sites. Thromb Res 13:345, 1978
180. Boyer MH, Shainoff JR, Ratnoff OD: Acceleration of fibrin polymerization by calcium ions. Blood 39:382, 1972
181. Laudano AP, Doolittle RF: Studies on synthetic peptides that bind to fibrinogen and prevent fibrin polymerization. Structural requirements, number of binding sites, and species differences. Biochemistry 19:1013, 1980
182. Laudano AP, Doolittle RF: Influence of calcium ion on the binding of fibrin amino terminal peptides to fibrinogen. Science 212:457, 1981
183. Laudano AP, Cottrell B A, Doolittle RF: Synthetic peptides modeled on fibrin polymerization sites. Ann NY Acad Sci 408:315, 1983
184. Lorand L, Losowsky MS, Miloszewski KJ: Human factor XIII: Fibrin-stabilizing factor. Prog Hemost Thromb 5:245, 1980
185. Purves L, Purves M: The structure of the human fibrin gamma-chain crosslink, in Mosesson MW, Amrani DL, Siebenlist KR, DiOrio JP (eds): Fibrinogen 3. Biochemistry, Biological Functions, Gene Regulation and Expression. Amsterdam, The Netherlands, Elsevier Science, 1988, p 95
186. Kloczewiak M, Timmons S, Hawiger J: Localization of a site interacting with human platelet receptor on carboxy-terminal segment of human fibrinogen γ chain. Biochem Biophys Res Commun 107:181, 1982
187. Farrell DH, Thiagarajan P, Chung DW, Davie EW: Role of fibrinogen α and γ chain sites in platelet aggregation. Proc Natl Acad Sci USA 89:10729, 1992
188. Weisel JW, Nagaswami C, Vilaire G, Bennett JS: Examination of the platelet membrane glycoprotein IIb-IIIa complex and its interaction with fibrinogen and other ligands by electron microscopy. J Biol Chem 267:16637, 1992
189. Carrell N, Gabriel DA, Blatt PM, Carr ME, McDonagh J: Hereditary dysfibrinogenemia in a patient with thrombotic disease. Blood 62:439, 1983
190. Collet J-P, Soria J, Mirshahi M, Hirsch M, Dagonnet FB, Caen J, Soria C: Dusart syndrome: A new concept of the relationship between fibrin clot architecture and fibrin clot degradability: Hypofibrinolysis related to an abnormal clot structure. Blood 82:2462, 1993
191. Lijnen HR, Soria J, Soria C, Collen D, Caen JP: Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost 51:108, 1984
192. Ieko M, Sawada K, Sakurama S, Yamagishi I, Isogawa S, Nakagawa S, Satoh M, Yasukouchi T, Matsuda M: Fibrinogen Date: Congenital hypodysfibrinogenemia associated with decreased binding of tissue-plasminogen activator. Am J Hematol 37:228, 1991
193. Gabriel DA, Muga K, Boothroyd EM: The effect of fibrin structure on fibrinolysis. J Biol Chem 267:24259, 1992
194. Nachman RL, Silverstein R: Hypercoagulable states [see comments]. Ann Intern Med 119:819, 1993
195. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlback B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U: Inherited thrombophilia: Part 1. Thromb Haemost 76:651, 1996
196. Schorer AE, Singh J, Basara ML: Dysfibrinogenemia: A case with thrombosis (fibrinogen Richfield) and an overview of the clinical and laboratory spectrum. Am J Hematol 50:200, 1995
197. Hessel B, Silveira AM, Carlsson K, Oksa H, Rasi V, Vantera E, Procyk R, Blombäck B: Fibrinogenemia Tampere - A dysfibrinogenemia with defective gelation and thromboembolic disease. Thromb Res 78:323, 1995
198. Lane DA, VanRoss M, Kakkar W, Bottomley KJ, Dhir K, Holt LP, Maclver JE: An abnormal fibrinogen with delayed fibrinopeptide A release. Br J Haematol 46:89, 1980
199. Ruf W, Bender A, Lane DA, Preissner KT, Selmayr E, Müller-Bergbaus G: Thrombin-induced fibrinopeptide B release from normal and variant fibrinogens: Influence of inhibitors of fibrin polymerization. Biochim Biophys Acta 965:169, 1988
200. Furlan M, Stucki B, Steinmann C, Jungo M, Lämmle B: Normal binding of calcium to five fibrinogen variants with mutations in the carboxy terminal part of the γ-chain. Thromb Haemost 76:377, 1996